top of page
Eli Lilly Just Bought AtaiBeckley for $3.8 Billion. The Market's Cheering. We're Not So Sure.
Big Pharma doesn't chase fringe science. Not unless the data forces its hand. That's what makes this week's news notable. On July 16, 2026, Eli Lilly (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley Inc. (Nasdaq: ATAI) — the psychedelic-medicine company formed less than a year ago through the merger of Germany's atai Life Sciences and the UK's Beckley Psytech. It's Lilly's first move into psychedelics, and it comes on the heels of a broader acquisition spre
Rebellionaire Staff
Jul 163 min read
Crypto Chaos: Tesla, Bitcoin, and the Market Freakout
Tesla Takes a Hit—But Why? Alright, so let’s talk about the chaos that just went down. Tesla, Bitcoin, and the market freakout. Tesla...
Rebellionaire Staff
Feb 26, 20253 min read
Unveiling the Potential of MAIA Biotechnology: A Game-Changer in Cancer Treatment
MAIA Biotechnology stands out with its innovative approach to cancer treatment.
Bradford Ferguson
Jun 15, 20243 min read
bottom of page